- Market Capitalization, $K 187,228
- Shares Outstanding, K 25,267
- Annual Sales, $ 2,600 K
- Annual Income, $ -73,810 K
- 60-Month Beta 0.58
- Price/Sales 70.47
- Price/Cash Flow N/A
- Price/Book 2.28
|Period||Period Low||Period High||Performance|
| || |
+0.53 (+7.51%)since 11/07/23
| || |
-2.24 (-22.79%)since 09/07/23
| || |
+2.79 (+58.12%)since 12/07/22
Verastem: Q3 Earnings Snapshot
Verastem: Q2 Earnings Snapshot
Morning Markets June E-Mini S&P 500 futures (ESM23 ) this morning are up +0.19%, and June Nasdaq 100 E-Mini futures (NQM23 ) are up +0.37%. U.S. stock index futures this morning are moderately higher....
June S&P 500 futures (ESM23) are up +0.10%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.30% this morning after three major U.S. benchmark indices rallied on Thursday as a series of economic data...
Morning Markets The S&P 500 Index ( $SPX ) ( SPY ) is up +0.47%, the Dow Jones Industrials Index ( $DOWI ) ( DIA ) is up $0.69%, and the Nasdaq 100 Index ( $IUXX ) ( QQQ ) is up +0.37%. U.S. stock index...
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END
/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....
Verastem: Q1 Earnings Snapshot
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that an abstract highlighting updated interim results from...